Is the longevity craze the same everywhere?

Important caveat on evidence quality: this is a genuinely thin dataset for the core ask. Despite 300 items scanned across 16 sources, only 45 Xiaohongshu notes and a single Weibo post surfaced with usable signal, and no direct Xiaohongshu/Weibo consumer-quote clusters made it into the ranked evidence — most of what's citable is Western media/YouTube/Reddit commentary about longevity culture, not raw cross-platform consumer chatter. Treat the China-vs-West comparison below as directional, not proven.

1. Longevity culture is increasingly framed by critics as a "grift" or "ageism in a lab coat" rather than science — this is the closest thing to a repeated claim in the data, but it's really two single-source signals converging on the same idea rather than a true multi-source consensus. Reddit's r/medicine tears into Bryan Johnson-style biohacking as a program that "targets a lack of trust in current medical institutions and our own societal insecurities about aging and death" dressed up as science[1]. The Guardian's "anti-ageing is anti-life" piece makes the parallel argument that longevity culture is just old-fashioned fear of ageing repackaged with lab-coat legitimacy[2]. (Loud but unconfirmed at true multi-source scale — 2 independent sources making the same critique, which counts as emerging agreement.)

2. Emerging agreement that "actually works" claims are being fact-checked hard on mainstream platforms. A YouTube deep-dive explicitly checked "every anti-aging claim on Sephora's shelf" against the reality that the FDA has approved exactly one topical ingredient as clinically proven to reduce wrinkles[3], and TikTok content shows consumers openly asking dermatologists "is this a real brand or a scam?" about botanical/skin-nutrition products[4]. Both point to a live undercurrent of ingredient-literacy and scam-skepticism on video platforms, even though each is single-sourced individually.

3. China's discourse (what little surfaced) is framed as a definitional/positioning problem, not a hype-vs-skeptic fight like the West. A 36Kr piece on China's "trillion-yuan anti-ageing market" quotes L'Oréal's Asia R&D director distinguishing "抗衰老" (anti-ageing, reactive repair/concealment of visible signs) from "整合长寿" (integrated longevity, proactive defense targeting root causes of skin ageing)[5] — a framing/marketing distinction rather than a consumer trust battle. This is single-source and doesn't show actual Xiaohongshu/Weibo user sentiment, which is a real gap given both platforms were in scope and Xiaohongshu returned 45 items with no citable comparison quotes.

4. Regenerative-medicine and peptide/exosome products are the specific flashpoint for regulator-style criticism in Asia-facing coverage. Tatler Asia's biohacking piece flags that stem cells and exosomes appear constantly in anti-ageing/med-aesthetic marketing despite the FDA stating no exosome product is currently approved, and separately warns about counterfeit/mislabeled compounded semaglutide and tirzepatide products circulating under the "biohacking" umbrella[6]. Single-source, but specific and concrete enough to flag as a genuine practitioner-adjacent warning theme.

5. A parallel, distinct-audience thread on Rumble frames aggressive interventions (e.g., high-dose glutathione) as "real anti-aging" curing "incurable disease" — low engagement (2,450 views, 5 comments) but notable as a contrast in register: alt-health video platforms use much more absolute/curative language than the hedged "may support" language typical of TikTok/YouTube mainstream creators[7]. Single-source, low-confidence signal.

What's missing, honestly: the brief cannot deliver a real US-vs-China-vs-Europe consumer-reaction comparison from this pull. Reddit skews toward biohacker-grift criticism (practitioner-adjacent, r/medicine), TikTok skews toward ingredient/scam skepticism, YouTube skews toward claim fact-checking, and China-side sources (Xiaohongshu, Weibo, 36Kr) returned volume but almost no citable comparative consumer sentiment in the evidence provided. Europe is nearly absent except via The Guardian's cultural-critique framing. This is a low-novelty, high-uncertainty brief — the crowd signal here mostly restates or lightly extends mainstream skepticism about longevity-industry hype rather than revealing a sharp, non-obvious regional divide.